Paul has over 30 years’ experience in the biotechnology and pharmaceutical sectors having held senior positions at Microgenics, Boeringher Mannheim, Acumen Biosciences, and, most recently, Horizon Discovery plc. In addition, over a 3-year period working in conjunction with Novo Nordisk, he worked on the downstream process of Factor VII. He has a strong and proven track record in business, commercial and product innovation/ development and, as a business entrepreneur, has helped to found numerous biotechnology and technology companies over the past 14 years, including a commercial founder of Horizon Discovery Group plc.

Over the past 9 years, as President of Products at Horizon Discovery Group, plc, Paul was instrumental in forming a bioprocessing group that focused on creating gene-edited CHO cell lines that could impact the growing need within the industry for improved bioproducer cell lines. In addition, he led the efforts of standardization within the Molecular Diagnostics (including NGS, FISH and IHC) industries by creating a range of highly characterized cell based reference standards that allow for platform/assay/operator comparison and standardization. Paul originated and built the products group at Horizon Discovery, which encompassed Diagnostics, Bioproduction, and Engineered cell lines.

Paul holds a PhD in Biotechnology from the University of Cambridge, is the author and contributor of several peer reviewed papers and patents in the fields of diagnostics, down-stream processing and imaging arrays.